Document 0252
 DOCN  M9460252
 TI    HIV-1 gp120 and anti-gp120 induce reversible unresponsiveness in
       peripheral CD4 T lymphocytes.
 DT    9404
 AU    Liegler TJ; Stites DP; Department of Laboratory Medicine, University of
       California, San; Francisco.
 SO    J Acquir Immune Defic Syndr. 1994 Apr;7(4):340-8. Unique Identifier :
       AIDSLINE MED/94180307
 AB    Human immunodeficiency virus type 1 (HIV-1) gp-120 potentially plays an
       important role in inducing functional suppression and depletion of CD4
       lymphocytes following infection with HIV. In order to further understand
       the mechanisms involved in HIV-induced immunosuppression, we have
       studied the effects of recombinant HIV-1 gp120/SF2 and anti-gp120/SF2
       antibodies on T cell receptor (TCR)-mediated proliferation of peripheral
       blood mononuclear cells (PBMCs) and isolated lymphocyte subsets from
       HIV-seronegative donors. In a dose-dependent manner, gp120 significantly
       reduces the proliferative responses of unfractionated PBMCs and highly
       enriched CD4 T lymphocytes when they are polyclonally stimulated through
       the TCR using WT31 (anti-alpha beta Ti chains) and anti-Leu 4 (anti-CD3
       epsilon) in the presence of autologous accessory cells. The addition of
       divalent anti-gp120/SF2 to lymphocytes previously incubated with gp120
       further reduces the proliferation to the levels seen after pretreating
       cells with divalent anti-CD4 (anti-Leu 3a). CD8 T lymphocytes, on the
       other hand, show no change in TCR-mediated proliferation following
       preincubation with either anti-CD4 or gp120/anti-gp120. We find no
       evidence for significant cell death by apoptosis using methods of DNA
       analysis or flow cytometry and DNA-specific dyes to account for the loss
       of CD4 lymphocyte proliferation. Interleukin-2 restores the
       proliferation suppressed by gp120/anti-gp120 suggesting the induction of
       reversible functional anergy.
 DE    Antibodies, Monoclonal/*IMMUNOLOGY  Antigens, CD4/IMMUNOLOGY  Cell
       Survival  Dose-Response Relationship, Immunologic  Human  HIV
       Antibodies/IMMUNOLOGY  HIV Envelope Protein gp120/*IMMUNOLOGY  *HIV
       Seronegativity  HIV-1/*IMMUNOLOGY  Interleukin-2/IMMUNOLOGY  Leukocytes,
       Mononuclear/IMMUNOLOGY  Lymphocyte Subsets/IMMUNOLOGY  Lymphocyte
       Transformation  Receptors, Antigen, T-Cell/IMMUNOLOGY  Recombinant
       Proteins/IMMUNOLOGY  Support, U.S. Gov't, P.H.S.  T4
       Lymphocytes/*IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).